{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-002059","form_type":"8-K","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.266143+00:00","generated_at":"2026-06-07T02:11:58.928442+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Immunome licenses Zentalis' ROR1 ADC ZPC-21 and ADC platform for $35M upfront, up to $275M milestones","bullets":["Exclusive worldwide license for preclinical ROR1 ADC ZPC-21; IND submission targeted for 1Q 2025.","Upfront consideration: $35M in cash and Immunome common stock (2,298,586 shares).","Zentalis eligible for up to $275M in milestone payments plus mid-to-high single-digit royalties.","Immunome gains Zentalis' proprietary ADC platform technology for additional programs.","Zentalis agrees to standstill restrictions and share transfer limitations for one year."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-002059","json":"https://secwatch.observer/filing/0001104659-24-002059.json","markdown":"https://secwatch.observer/filing/0001104659-24-002059.md","text":"https://secwatch.observer/filing/0001104659-24-002059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000110465924002059/0001104659-24-002059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000110465924002059/tm242340d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:11:58.928442+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"385c0f7831b5cd7f4a94bf8bec4734a6689b7701","claim":"Immunome Inc. entered into Stock Issuance Agreement with Zentalis Pharmaceuticals, Inc. (effective 2024-01-05).","evidence_excerpt":"Concurrently with the execution of the License Agreement, the Company entered into a stock issuance agreement (the “Stock Issuance Agreement”) with Zentalis, pursuant to which the Company issued 2,298,586 shares of the Company’s common stock (the “Shares”), as partial consideration for the rights licensed to the Company from Zentalis pursuant to the License Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472012/000110465924002059/0001104659-24-002059-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Zentalis Pharmaceuticals, Inc."},{"label":"Effective","value":"2024-01-05"}],"fact_type":"material_agreement"},{"claim_id":"7ba4bc5b133da2e4e565ac30e15c7e38a0a827a1","claim":"Immunome Inc. entered into License Agreement with Zentalis Pharmaceuticals, Inc. valued at $35 million (effective 2024-01-05).","evidence_excerpt":"On January 5, 2024, Immunome, Inc. (the “Company”) entered into a license agreement (“License Agreement”) with Zentalis Pharmaceuticals, Inc. (“Zentalis”), pursuant to which the Company received an exclusive, worldwide, royalty-bearing, sublicensable license under certain intellectual property relating to Zentalis’ proprietary antibody-drug conjugate (“ADC”) platform technology, ROR1 antibodies and ADCs targeting ROR1 to exploit products covered by or incorporating the licensed intellectual property rights.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472012/000110465924002059/0001104659-24-002059-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Zentalis Pharmaceuticals, Inc."},{"label":"Value","value":"$35 million"},{"label":"Effective","value":"2024-01-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}